838 results on '"Shipley, William U."'
Search Results
202. 1456: Recursive Partitioning Analysis of Predictors of Distant Metastasis for Men with Prostate Cancer Treated with Radiotherapy and Androgen Deprivation on RTOG 9202: The Impact of KI-67
203. 308: An Update of Selective Bladder Preservation Using Combined Modality Treatment in Invasive Bladder Cancer: Long Term Outcome Reveals a Low Risk of Invasive Recurrence and a High Probability of Bladder Preservation
204. Case 3-2004
205. In response to Drs. Kataria Sethi, Negi, and Rawat
206. RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy
207. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era
208. Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: Results from a 10-year cohort analysis
209. Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524—A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation
210. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10
211. Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer
212. AN ORGAN-PRESERVING APPROACH TO MUSCLE-INVADING TRANSITIONAL CELL CANCER OF THE BLADDER
213. Radiation oncology update
214. Bladder preservation in muscle‐invasive bladder cancer by conservative surgery and radiochemotherapy
215. GENITOURINARY MALIGNANCIES.
216. The Initial Results in Muscle-Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil Followed by Selective Bladder Preservation or Cystectomy Depending on the Initial Response
217. Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer—results from a pilot study
218. Proton Beam Therapy in Localized Prostate Cancer
219. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy
220. AN UPDATE OF COMBINED MODALITY THERAPY FOR PATIENTS WITH MUSCLE INVADING BLADDER CANCER USING SELECTIVE BLADDER PRESERVATION OR CYSTECTOMY
221. Radiation Therapy for Clinically Localized Prostate Cancer: A Multi-institutional Pooled Analysis
222. Bladder Preservation Trial: Radiation Therapy Oncology Group 89-03
223. The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer
224. Management of Carcinoma of the Bladder
225. Bladder cancer: The combination of chemotherapy and irradiation in the treatment of patients with muscle-invading tumors
226. Combined modality therapy as a means of blandder preservation for invasive bladder cancer
227. Invasive bladder cancer: Treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation
228. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer
229. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer
230. Bowenoid Papulosis: A Benign Lesion of the Shaft of the Penis Misdiagnosed as Squamous Carcinoma
231. Bowenoid Papulosis
232. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: Experimental and clinical results
233. 203 Bladder cancer: The combination of chemotherapy and irradiation in the treatment of patients with muscle-invading tumors
234. 1004 The value of external beam radiation in pathologic node positive prostate cancer: A multivariate analysis
235. Androgen deprivation and radiation therapy in prostate cancer: The evolving case for combination therapy
236. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer
237. Conformal irradiation of the prostate: Estimating long-term rectal bleeding risk using dose-volume histograms
238. PSA following irradiation for prostate cancer: The Upcoming Astro Symposium
239. The management of spermatic cord sarcoma
240. Translational research in bladder cancer
241. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease
242. An update of RTOG clinical trials of combined androgen suppression and radiation in localized prostatic carcinoma
243. 2053 Probability of subsequent failure in men with prostate cancer clinically disease free 10 years after treatment with radiation therapy
244. 203 Bladder cancer: The combination of chemotherapy and irradiation in the treatment of patients with muscle-invading tumors
245. 141 Overall survival and local control following combined modality therapy and selective bladder preservation for invasive bladder cancer
246. The treatment of prostate cancer by conventional radiation therapy: An analysis of long-term outcome
247. Bladder Preservation Strategies
248. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology group
249. Potential location of a bladder tumor suppressor gene on chromosome 9q at 9q13 to 9q22.1
250. 1055 Prostate cancer: Estimating long-term rectal bleeding risk using dose-volume histograms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.